Back to School: How biopharma can reboot drug development. Access exclusive analysis here

CMX001: Phase III start

Mid-year, Chimerix will begin the double-blind, placebo-controlled Phase III SUPPRESS trial to evaluate 100 mg CMX001 twice weekly for 14 weeks in about 450

Read the full 247 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE